외음질 이식편대숙주병: 진단 및 미생물군집 평가
The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD. This study aims to characterize the vaginal microbiome in participants undergoing allogeneic hematopoietic cell transplantation (HCT). The main questions it aims to answer are:
- Is the vaginal microbiome altered during allogeneic HCT?
- What changes may help researchers understand the development of vulvovaginal GVHD?
Participants will be asked to undergo an assessment of vulvovaginal symptoms through a vulvovaginal symptom questionnaire once pre-transplant, 6 months post-transplant, and twelve12 months post- transplant. Participants will also be asked to undergo a vaginal microbiome (collection of bacteria, fungi, and viruses that live on our bodies) evaluation through a vaginal exam performed by a gynecologist with collection of vaginal samples once pre-transplant and again six months post-treatment and twelve months post-transplant. If a participant develops symptoms of vulvovaginal GVHD at any point in time during the post-transplant follow up, the participant may partake in additional vaginal exams to diagnose GVHD at the time of symptom onset.
연구 개요
상태
상세 설명
Recent advances in technologies including high throughput metagenomic 16S rRNA gene sequencing have revealed a larger, more complex picture of the bacterial diversity in the genital tract and unique microbial communities not previously recognized among the known vaginal flora categories. Little is known about how the vaginal microbiome protects the female genital tract or other roles it may have, including interacting with the microbiota of other body sites and subsequent inflammatory responses. Alteration of vaginal flora may play a part in the pathogenesis of diseases by modulating immunity or increasing the growth of pathogenic strains. Recent research has been conducted regarding changes in the vaginal microbiome during various infectious and inflammatory states such as bacterial vaginosis, pelvic inflammatory disease, sexually transmitted infectious, and pregnancy. However, the vaginal microbiome during allogeneic HCT and development of genital GVHD has yet to be examined. Thus, the role of the vaginal microbiome in the development of genital GVHD is a critical area of study.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Betty K Hamilton, MD
- 전화번호: 1-866-223-8100
- 이메일: TaussigResearch@ccf.org
연구 장소
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- 모병
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
연락하다:
- Betty, MD
- 전화번호: 866-223-8100
- 이메일: TaussigResearch@ccf.org
-
수석 연구원:
- Betty K Hamilton, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Female participants undergoing allogenic HCT will be recruited from the Blood and Marrow Transplant Program at the Cleveland Clinic.
설명
Inclusion Criteria:
- Female participants planning to undergo allogeneic HCT for any disease indication, OR, female participants who have already received HCT and have developed vulvovaginal GVHD during their post-transplant follow-up period
- All conditioning regimens (myeloablative or reduced intensity) will be included.
- All donor sources (HLA matched/mismatched related, unrelated, umbilical cord, haploidentical) will be included.
- All graft sources (bone marrow or peripheral blood stem cells) will be included.
- All GVHD prophylaxis regimens will be included.
- Aged 18-70.
- English speaking and able to sign written informed consent.
- Participants agree to a vaginal gynecologic exam.
- Co-enrollment on other clinical trials will be allowed.
Exclusion Criteria:
- Participants who decline or unable to undergo vaginal gynecologic exam due to any discomfort or pain.
- Any concurrent medical, psychiatric or other illness in which the provider believes the participants may not be able to comply with study assessments.
- Participants with a current diagnosis of a sexually transmitted infection (STI) (Herpes Simplex Virus, Gonorrhea, Chlamydia, Trichomonas,) or a history of previously untreated STI which may incite inflammation that will impact the microbiome.
- Participants with a history of lichen sclerosis, lichen planus, pre-transplant.
- Participants with a history or current diagnosis of vaginal or vulvar malignancy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Allogeneic HCT participants
The cohort will be comprised of participants undergoing allogeneic HCT at the Cleveland Clinic. |
Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant. A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Characterize the vaginal microbiome profile of female participants undergoing allogeneic HCT
기간: Up to twelve months post-transplant
|
A primary objective of this study is to characterize the vaginal microbiome and in female participants undergoing allogeneic HCT. |
Up to twelve months post-transplant
|
|
Characterize the change in vaginal microbiome profile of female participants undergoing allogeneic HCT
기간: Up to twelve months post-transplant
|
A primary objective of this study is to characterize the vaginal microbiome change in female participants undergoing allogeneic HCT. |
Up to twelve months post-transplant
|
|
Incidence of vulvovaginal GVHD
기간: Up to twelve months post-transplant
|
A primary objective is to measure the incidence of vulvovaginal GVHD in this cohort. |
Up to twelve months post-transplant
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Characterize the differences in vaginal microbiome between participants who develop vulvovaginal GVHS versus those who do not
기간: Up to twelve months post-transplant
|
The secondary objective is to investigate differences in vaginal microbiome between participants who develop vulvovaginal GVHD and those who do not. |
Up to twelve months post-transplant
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Betty K Hamilton, MD, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CASE2Z24
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .